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“Go low” or say “No”  
to aggressive systolic BP goals? 
The SPRINT trial demonstrated the benefits—and risks—
of reaching a systolic target <120 mm Hg in non-diabetic 
patients at high risk for CV events. Here’s who might benefit.
PRACTICE CHANGER 
Consider treating non-diabetic patients 
age ≥50 years to a systolic blood pressure 
(SBP) target <120 mm Hg as compared to 
<140 mm Hg when the benefits—lower rates 
of fatal and nonfatal cardiovascular (CV) 
events and death from any cause—are likely 
to outweigh the risks from possible additional 
medication.1 
STRENGTH OF RECOMMENDATION
B: Based on a single, good-quality random-
ized controlled trial (RCT).
Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial 
of intensive versus standard blood-pressure control. N Engl J Med. 
2015;373:2103-2116. 
ILLUSTRATIVE CASE
A 55-year-old man with hypertension and 
stage 3 chronic kidney disease (CKD) comes in 
to your office for routine care. His blood pres-
sure is 135/85 mm Hg, and he is presently tak-
ing lisinopril 40 mg daily. Should you increase 
his antihypertensive regimen?
Hypertension is common and leads to significant morbidity and mor-tality, but pharmacologic treatment 
reduces incidence of stroke by 35% to 40%, 
myocardial infarction (MI) by 15% to 25%, 
and heart failure by up to 64%.2-4  Specific 
blood pressure targets for defined popula-
tions continue to be studied. 
In patients with diabetes, the ACCORD 
(Action to Control Cardiovascular Risk in 
Diabetes) trial found that more intensive BP 
targets did not reduce the rate of major CV 
events, but the study may have been under-
powered.5 The members of The Eighth Joint 
National Committee recommended treat-
ing patients over age 60 years to BP goals 
<150/90 mm Hg.6 This was based on evi-
dence from 6 randomized controlled trials 
(RCTs),7-12 but there remains debate—even 
among the members of the Committee—as 
to appropriate BP goals in patients of any age 
without CV disease who have BP measure-
ments of 140-159/90-99 mm Hg.13 
STUDY SUMMARY
Treating to SBP <120 mm Hg  
lowers mortality
The Systolic Blood Pressure Intervention Trial 
(SPRINT) was a multicenter RCT designed to 
determine if treating to lower SBP targets in 
non-diabetic patients at high risk for CV events 
improves outcomes as compared to standard 
care. Patients were at least 50 years of age with 
SBP of 130 to 180 mm Hg and were at increased 
CV risk as defined by clinical or subclinical 
CV disease other than stroke, CKD with glo-
merular filtration rate (GFR) 20 to 60 mL/min/ 
1.73 m2, 10-year risk of CV disease >15% on 
Framingham risk score, or age ≥75 years of 
age. Patients with diabetes; prior stroke; poly-
cystic kidney disease; significant proteinuria 
within the past 6 months; symptomatic heart 
failure within the past 6 months; or left ven-
tricular ejection fraction <35% were excluded.1
How likely are 
you to more  
aggressively treat 
hypertension in 
high-risk patients 
in light of the 
SPRINT trial  
findings? 
n  Not at all likely
n  Somewhat likely
n  Extremely likely
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Patients (N=9361) were randomly as-
signed to an SBP target <120 mm Hg in the 
intensive group or <140 mm Hg in the stan-
dard treatment group, in an open-label de-
sign. Allocation was concealed. The study 
protocol encouraged, but did not require, the 
use of thiazide-type diuretics, loop diuret-
ics (for those with advanced renal disease), 
angiotensin-converting enzyme inhibitors 
or angiotensin receptor blocker agents, cal-
cium channel blockers, and beta-blockers. 
Clinicians could add other agents as needed. 
All major classes of antihypertensives were 
used.
Medication dosing adjustments were 
based on the average of 3 BP measurements 
taken with an automated measurement sys-
tem (Omron Healthcare, Model 907) with the 
patient seated after 5 minutes of quiet rest. 
Target SBP in the standard therapy group was 
135 to 139 mm Hg. Medication dosages were 
lowered if SBP was <130 mm Hg at a single 
visit or <135 mm Hg at 2 consecutive visits.1
The primary composite outcome includ-
ed the first occurrence of MI, acute coronary 
syndrome, stroke, heart failure, or death from 
CV causes. Secondary outcomes were the in-
dividual components of the primary compos-
ite outcome, death from any cause, and the 
composite of the primary outcome or death 
from any cause.1 
❚ Study halted early. The study was 
stopped early due to significantly lower 
rates of the primary outcome in the inten-
sive therapy group vs the standard therapy 
group (1.65% per year vs 2.19% per year, re-
spectively, hazard ratio [HR] with intensive 
treatment=0.75; 95% confidence interval 
[CI], 0.64-0.89; P<.001). The resulting median 
follow-up time was 3.26 years.1 This corre-
sponds to a 25% lower relative risk of the pri-
mary outcome, with a decrease in event rates 
from 6.8% to 5.2% over the trial period. All-
cause mortality was also lower in the inten-
sive therapy group: 3.4% vs 4.5% (HR=0.73; 
95% CI, 0.60-0.90; P=.003).
The number needed to treat (NNT) over 
3.26 years to prevent a primary outcome 
event, death from any cause, and death from 
CV causes was 61, 90, and 172, respectively. 
Serious adverse events occurred more fre-
quently in the intensive therapy group than in 
the standard therapy group (38.3% vs 37.1%; 
HR=1.04; P=.25) with a number needed to 
harm (NNH) of 46 over the study period.1 
(When looking at serious adverse events 
identified as likely associated with the inter-
vention, rates were 4.7% vs 2.5%, respectively 
[P<.001].) Hypotension, syncope, electrolyte 
abnormalities, and acute kidney injury/acute 
renal failure reached statistical significance. 
The incidence of bradycardia and injurious 
falls was higher in the intensive treatment 
group, but did not reach statistical signifi-
cance. In the subgroup of patients ≥75 years 
of age, 48% in each study group experienced 
a serious adverse event.1
Throughout the study, mean SBP was 
121.5 mm Hg in the intensive therapy group 
and 134.6 mm Hg in the standard treatment 
group. This required an average of one addi-
tional BP medication in the intensive therapy 
group (2.8 vs 1.8, respectively).1
WHAT’S NEW
Lower SBP produces mortality benefits  
in those under, and over, age 75
This trial builds on a body of evidence that 
shows the advantages of lowering SBP to 
<150 mm Hg7,11,12 by demonstrating ben-
efits, including lower all-cause mortality, for 
lower SBP targets in non-diabetic patients at 
high risk of CV disease. The SPRINT trial also 
showed that the benefits of intensive thera-
py remained true in a subgroup of patients 
≥75 years of age. 
The incidence of the primary outcome 
in the cohort ≥75 years of age receiving in-
tensive therapy was 7.7% vs 10.9% for those 
receiving standard therapy (HR=0.67; 95% CI, 
0.51-0.86; NNT=31). All-cause mortality was 
also lower in the intensive therapy group than 
in the standard therapy group among patients 
≥75 years of age: 5.5% vs 8.04% (HR=0.68; 
95% CI, 0.50-0.92; NNT=38).1
CAVEATS
Many do not benefit from—or are  
harmed by—increased medication
The absolute risk reduction for the primary 
outcome is 1.6%, meaning 98.4% of patients 
receiving more intensive treatment will not 
In a group of 
1000 patients, 
an estimated 
16 patients will 
benefit from 
intensive BP 
treatment,  
22 patients will 
be seriously 
harmed, and 
962 patients will 
experience  
neither benefit 
nor harm.
344 THE JOURNAL OF FAMILY PRACTICE  |   MAY 2016  |   VOL 65, NO 5
PURLs®
Identifying 
patients  
most likely to 
benefit from 
more intensive 
blood pressure 
targets remains 
challenging.
benefit. In a group of 1000 patients, an esti-
mated 16 patients will benefit, 22 patients will 
be seriously harmed, and 962 patients will 
experience neither benefit nor harm.14 The 
difference between how BP was measured in 
this trial (an average of 3 readings after the pa-
tient had rested for 5 minutes) and that which 
occurs typically in clinical practice could po-
tentially lead to overtreatment in practice.  
Also, reducing antihypertensive ther-
apies when the SBP was about 130 to 
135 mm Hg in the standard therapy group 
likely exaggerated the difference in outcomes 
between the intensive and standard therapy 
groups, and is neither routine nor recom-
mended in clinical practice.6 Finally, the trial 
specifically studied non-diabetic patients at 
high risk of CV disease ≥50 years of age, limit-
ing generalizability to other populations. 
CHALLENGES TO IMPLEMENTATION
Who will benefit/who can achieve 
intensive SBP goals?
Identifying patients most likely to benefit 
from more intensive BP targets remains chal-
lenging. The SPRINT trial showed a mortality 
benefit, but at a cost of increased morbidity.1,14 
In particular, caution should be exercised in 
the subgroup of patients ≥75 years. Despite a 
lower NNT than the rest of the study popula-
tion, serious adverse events happened more 
frequently. Also, this particular cohort of vol-
unteers may not be representative of those 
≥75 years of age in the general population. 
Additionally, achieving intensive SBP 
goals can be challenging. In the SPRINT 
trial, only half of the intensive target group 
achieved an SBP <120 mm Hg.1 And in a 
2011-12 National Health and Nutrition Ex-
amination Survey, only 52% of patients in 
the general population achieved a BP target 
<140/90 mm Hg.15 Lower morbidity and mor-
tality should remain the ultimate goals to the 
management of hypertension, requiring phy-
sicians to carefully assess an individual pa-
tient’s likelihood of benefit vs harm.             JFP
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